8 completed, 1 terminated. 5 Phase 2, 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 2 | Completed 2 |
Follow Pegylated Interferon alfa 2a: new trials by email Literature Review of Pegylated Interferon alfa 2a trials Research Report on Pegylated Interferon alfa 2a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets - Chronic Hepatitis B | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 8 | 2022-08-23 | 2024-07-15 |
| Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir - Infection | Phase 3 | Terminated | M.D. Anderson Cancer Center | 1 | 2013-04-01 | 2020-09-24 |
| Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy Educational Intervention, Patient education and management skills training - Chronic Hepatitis C, Genotype 1 | Phase 4 | Completed | Chronic Liver Disease Foundation | 197 | 2011-12-01 | 2015-01-06 |
| A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin - Hepatitis C | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 1095 | 2008-03-01 | 2014-08-08 |
| A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy Telaprevir, Ribavirin, Pegylated interferon alfa 2a - Hepatitis C | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 117 | 2007-10-01 | 2014-08-05 |
| A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a - Hepatitis C | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 465 | 2007-02-01 | 2014-08-05 |
| Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C Ribavirin, Pegylated Interferon Alfa 2a, Placebo - Chronic Hepatitis C | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 334 | 2006-08-01 | 2014-07-23 |
| Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a - Chronic Hepatitis C | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 263 | 2006-06-01 | 2014-07-23 |
| Australian Trial in Acute Hepatitis C Pegylated Interferon alfa 2a, Ribavirin (HIV conifected patients only) - Hepatitis C | Phase 4 | Completed | Kirby Institute | 167 | 2004-07-01 | 2011-04-15 |
Hepatitis C (5) · Hepatitis C, Chronic (3) · Carcinoma, Hepatocellular (1) · Hepatitis B, Chronic (1) · Infections (1)
Vertex Pharmaceuticals Incorporated (5) · Chronic Liver Disease Foundation (1) · Kirby Institute (1) · M.D. Anderson Cancer Center (1) · Shanghai HEP Pharmaceutical Co., Ltd. (1)
United States (6) · Germany (4) · Puerto Rico (4) · Austria (3) · Canada (3) · France (3) · United Kingdom (3) · Australia (2) · Netherlands (2) · Argentina (1) · China (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1)
Fred Poordad, MD (1) · Greg Dore, MB BS FRACP (1) · Harrys A. Torres, MD (1) · John Kaldor, PhD (1) · Nathalie Adda, MD (1) · Qin Zhang (1)
PMID 19403902, PMID 19403903, PMID 20375406, PMID 21145855, PMID 21282185, PMID 21690488, PMID 21696307, PMID 25105742, PMID 26115881, PMID 26327916, PMID 27246604, PMID 27355323